Physician profile
Michael Egann
NPI 1538149281
$3,616.40
in general payments reported to CMS, 2019-2025
15 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $540 · 2021: $905 · 2022: $609 · 2023: $149 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.20 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.94 | 2019-2023 | Rinvoq |
| Amgen INC. | $653.86 | 2019-2022 | |
| Lilly USA, LLC | $451.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $358.71 | 2019 | |
| Pfizer INC. | $217.13 | 2019-2022 | |
| Janssen Biotech, INC. | $171.98 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $155.40 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $134.75 | 2019 | |
| Celgene Corporation | $127.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $111.49 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $86.09 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $28.11 | 2021 | |
| Horizon Therapeutics Plc | $26.83 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Egann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.